BRD73954 does not only retained HDAC6 inhibitory activity (IC50 = 0.036 μM) but resulted in a 10-fold increase in potency for HDAC8 (IC50 = 0.12 μM) with a concomitant reduction in potency for HDAC2.
In vitro: While treatment BRD73954 with resulted in a robust increase in α-tubulin acetylation, no change in the acetylation state of H3 was observed, which is consistent with the ability of these compounds to inhibit HDAC6 but not HDACs 1, 2, or 3 in the biochemical assay in HeLa cells.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 30 mg/mL|
Discovery of the first histone deacetylase 6/8 dual inhibitors.
Olson DE, et al. J Med Chem. 2013 Jun 13;56(11):4816-20. PMID: 23672185.
|Related HDAC Products|
WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM.
EDO-S101 is a pan HDAC inhibitor; inhibits HDAC1, HDAC2 and HDAC3 with IC50 values of 9, 9 and 25 nM, respectively.
Citarinostat (ACY-241) is an orally available selective HDAC6 inhibitor with IC50 of 2.6 nM and 46 nM for HDAC6 and HDAC3, respectively. It has 13 to 18-fold selectivity towards HDAC6 in comparison to HDAC1-3.
Sodium butyrate is the sodium salt of butyric acid, which has been reported to cause hyperacetylation of histones due to its role as a HDAC inhibitor with IC50 values of 0.3, 0.4, 0.3 mM for HDAC1, 2 and 7 respectively.
LMK235 is a HDAC inhibitor, previously shown to be a novel and specific inhibitor of human HDAC4 and 5, with IC50 values of 0.49 μM (A2780) and 0.32 μM (A2780 CisR).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.